“It’s time to respond … [to Americans who] have not been given a comprehensive explanation of how U.S. investments in foreign aid — particularly global health — are used or how they benefit Americans here at home,” Karl Hofmann, president and CEO of PSI, writes in a Huffington Post opinion piece. “Global health investments benefit the globe. … Healthy families yield healthy societies and economies. Everyone everywhere benefits,” he states.
“For the Bill & Melinda Gates Foundation, the Global Fund [to Fight AIDS, Tuberculosis and Malaria] is an invaluable partner, and the progress they have achieved is bringing us closer than ever to the reality of global health equity,” Joe Cerrell, director of the Gates Foundation’s European office, writes in an AlertNet opinion piece, adding, “Every day, programs supported by the Global Fund save at least 4,400 lives.”
In this post in the Guardian’s “Sustainable Business Blog,” Mark Kramer, founder and managing director of the non-profit consulting firm FSG and senior fellow at the CSR Initiative at the Harvard Kennedy School of Government, examines how “[g]lobal corporations are increasingly finding ways to create shared value — pursuing business initiatives that improve social and environmental conditions while earning the company a profit and conferring a competitive advantage.”
“The global health community has come to appreciate the potential of mHealth,” but the technology’s use for health programs in developing countries ”remains in its infancy, with many of the characteristics and issues typical of young industries,” Amanda Glassman of the Center for Global Development (CGD) and Vicky Hausman of Dalberg Global Development…
A lack of water and poor sanitation, a result of rapid urbanization being experienced in big cities and small towns throughout the developing world, urgently need tackling in order to curb the resulting spread of diarrheal disease “in what the U.N. terms ‘informal settlements’ — slums, as they are more commonly known,” Timeyin Uwejamomere, senior policy analyst for urban water and sanitation services at WaterAid, writes in this post in the Guardian’s “Poverty Matters Blog.”
In this Foreign Policy Association blog post, freelance writer Julia Robinson calls for individuals to start demanding more action on non-communicable diseases (NCDs), writing, “It is possible to have stronger responses to NCDs” than those presented in the political declaration that resulted from last month’s U.N. High-level Meeting (HLM) on…
In a Huffington Post opinion piece, Kolleen Bouchane, director of ACTION, asks whether President Barack Obama will “heed Archbishop [Desmond] Tutu’s call to action” in a recent Washington Post opinion piece “and do his part to end AIDS.” She says, “While campaigning, President Obama promised to expand PEPFAR ‘by $1 billion a year in new money over the next five years’ and provide $50 billion by 2013 to fight HIV/AIDS worldwide. We are not on track to see even those promises become reality. We are not on track for the leadership to change the course of HIV and AIDS that Tutu has called for.”
In this post in LA Progressive, Georgianne Nienaber, an investigative and political writer, examines the potential effects of reduced PEPFAR funding and highlights the non-denominational Christian ACTS clinic operating in South Africa as an example of a U.S. foreign aid success story. She writes, “At ACTS, PEPFAR funding supports a…
Maintaining Commitment Amid Promising Scientific Advances Is Necessary To Make AIDS Vaccine A Reality
In this Huffington Post opinion piece, Mitchell Warren, executive director of AVAC: Global Advocacy for HIV Prevention, examines the need for continued attention and funding for additional research for an AIDS vaccine, highlighting advancements presented at the AIDS Vaccine 2011 conference in Bangkok, Thailand earlier this month. He writes, “We don’t yet have a blueprint for an effective vaccine to roll-out. But, as presented this week in Bangkok, the complex success of the RV144 analysis, combined with a flurry of advances in understanding the development of broadly-neutralizing antibodies against HIV, show that the science of an AIDS vaccine is vibrant and vital. Now is exactly the time to maintain commitment.”
Based on a report released last week by a high-level independent review panel on fiduciary controls and oversight mechanisms at the Global Fund to Fight AIDS, Tuberculosis and Malaria, “[t]he changes needed at the Fund are clearly substantial,” according to a Lancet editorial. “However, as the report notes, there is ‘nothing that cannot be fixed by appropriate reform.’ Whether governments in this era of austerity will stick by the Fund as it evolves is now a major concern. But there are good reasons for donors to keep funding the Global Fund,” the editorial states.